OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SUNA58

Sunway Healthcare Holdings Bhd

Healthcare Facilities & ServicesVerified

Sunway Healthcare Holdings Bhd has a debt-to-equity ratio of 0.64, indicating a moderate level of leverage, and a current ratio of 1.13, suggesting limited short-term liquidity cushion. The company's free cash flow is negative at -126,558,000 MYR, which is a concern for its ability to fund operations without external financing. The capital expenditure of -579,051,000 MYR indicates significant investment in long-term assets. The company's profitability is reflected in a return on equity of 10.01% and a return on assets of 5.21%, which are metrics that are typically used in the healthcare industry to assess performance. The operating income of 310,136,000 MYR and net income of 252,212,000 MYR suggest a healthy margin, but the gross profit of 1,383,219,000 MYR indicates that the company is managing its cost of goods sold effectively. Sunway Healthcare Holdings Bhd's revenue is concentrated in the pharmaceuticals segment, and there is no detailed breakdown of geographic exposure provided in the available data. The company's revenue of 2,200,389,000 MYR is a key indicator of its market position within the healthcare facilities and services industry. The company's growth trajectory is not explicitly detailed in the available data, but the negative free cash flow and significant capital expenditure suggest that the company is investing in its future growth. The operating cash flow of 465,659,000 MYR indicates that the company is generating positive cash from its operations, which is a positive sign for its financial health. The risk assessment indicates a medium liquidity risk and a low dilution risk, with a key flag noting that net cash is negative after subtracting total debt. The company's dilution potential is low, and there are no adjustments applied to the valuations that would suggest a significant risk of dilution. Recent events and filings are not detailed in the available data, but the company's financial snapshot and valuation metrics provide a current view of its financial position.

30-day price · SUNA-0.09 (-4.8%)
Low$1.75High$1.98Close$1.78As of25 May, 00:00 UTC
Profile
CompanySunway Healthcare Holdings Bhd
TickerSUNA.KL
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Sunway Healthcare Holdings Bhd operates in the healthcare facilities and services industry, generating revenue primarily through pharmaceuticals and healthcare services.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Sunway Healthcare Holdings Bhd has a debt-to-equity ratio of 0.64, indicating a moderate level of leverage, and a current ratio of 1.13, suggesting limited short-term liquidity cushion. The company's free cash flow is negative at -126,558,000 MYR, which is a concern for its ability to fund operations without external financing. The capital expenditure of -579,051,000 MYR indicates significant investment in long-term assets. The company's profitability is reflected in a return on equity of 10.01% and a return on assets of 5.21%, which are metrics that are typically used in the healthcare industry to assess performance. The operating income of 310,136,000 MYR and net income of 252,212,000 MYR suggest a healthy margin, but the gross profit of 1,383,219,000 MYR indicates that the company is managing its cost of goods sold effectively. Sunway Healthcare Holdings Bhd's revenue is concentrated in the pharmaceuticals segment, and there is no detailed breakdown of geographic exposure provided in the available data. The company's revenue of 2,200,389,000 MYR is a key indicator of its market position within the healthcare facilities and services industry. The company's growth trajectory is not explicitly detailed in the available data, but the negative free cash flow and significant capital expenditure suggest that the company is investing in its future growth. The operating cash flow of 465,659,000 MYR indicates that the company is generating positive cash from its operations, which is a positive sign for its financial health. The risk assessment indicates a medium liquidity risk and a low dilution risk, with a key flag noting that net cash is negative after subtracting total debt. The company's dilution potential is low, and there are no adjustments applied to the valuations that would suggest a significant risk of dilution. Recent events and filings are not detailed in the available data, but the company's financial snapshot and valuation metrics provide a current view of its financial position.
Key takeaways
  • Sunway Healthcare Holdings Bhd has a moderate level of leverage with a debt-to-equity ratio of 0.64.
  • The company's return on equity of 10.01% indicates strong profitability relative to its equity base.
  • The negative free cash flow of -126,558,000 MYR suggests the company may need to seek external financing to fund operations.
  • The company's operating cash flow of 465,659,000 MYR is a positive indicator of its ability to generate cash from operations.
  • The capital expenditure of -579,051,000 MYR indicates significant investment in long-term assets.
  • # RATIONALES
  • margin_outlook_rationale: The company's gross profit margin is strong, indicating effective cost management.
  • rd_outlook_rationale: No specific information is available to assess the company's research and development outlook.
Financial snapshot
PeriodHA-latest
CurrencyMYR
Revenue$2.20B
Gross profit$1.38B
Operating income$310.1M
Net income$252.2M
R&D
SG&A
D&A
SBC
Operating cash flow$465.7M
CapEx-$579.1M
Free cash flow-$126.6M
Total assets$4.84B
Total liabilities$2.32B
Total equity$2.52B
Cash & equivalents$141.2M
Long-term debt$1.62B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$2.52B
Net cash-$1.48B
Current ratio1.1
Debt/Equity0.6
ROA5.2%
ROE10.0%
Cash conversion1.9%
CapEx/Revenue-26.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricSUNAActivity
Op margin14.1%7.7% medp25 -2.4% · p75 15.5%above median
Net margin11.5%5.9% medp25 -3.8% · p75 12.8%above median
Gross margin62.9%45.5% medp25 31.1% · p75 62.9%above median
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-26.3%-7.0% medp25 -14.9% · p75 -3.2%bottom quartile
Debt / equity64.0%25.0% medp25 3.8% · p75 63.3%top quartile
Observations
IR observations
Mean price target1.92 MYR
Median price target1.96 MYR
High price target2.30 MYR
Low price target1.25 MYR
Mean recommendation2.43 (1=strong buy, 5=strong sell)
Strong-buy count2.00
Buy count1.00
Hold count3.00
Sell count1.00
Strong-sell count0.00
Mean EPS estimate0.02 MYR
Mean revenue estimate2,659,193,860 MYR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-24 21:25 UTC#651ee7e4
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 14:50 UTCJob: f9d7f567